1. < Home

safety

Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis

Rastogi A, Fishbane S, Lerma E. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. Expert Rev Clin Pharmacol. 2023[...]

By sjmartinez • April 4, 2023
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies

Khalil DN, Prieto González-Albo I, Rosen L, Lillie T, Stacey A, Parfitt L, Soff GA. A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without[...]

By sjmartinez • March 11, 2023
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn[...]

By sjmartinez • December 5, 2022
Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials

Hamid A, Anker MS, Ruckdeschel JC, Khan MS, Tharwani A, Oshunbade AA, Kipchumba RK, Thigpen SC, Anker SD, Fonarow GC, Hall ME, Butler J. Cardiovascular[...]

By sjmartinez • July 25, 2022